within Pharmacolibrary.Drugs.ATC.J;

model J05AE30
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.14983333333333335,
    adminDuration  = 600,
    adminMass      = 0.3,
    adminCount     = 1,
    Vd             = 0.1055,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018666666666666668,
    Tlag           = 13.2
  );

  annotation(Documentation(
    info ="<html><body><p>Nirmatrelvir and ritonavir is a combination antiviral therapy used primarily in the treatment of COVID-19. Nirmatrelvir is a SARS-CoV-2 3CL protease inhibitor, while ritonavir acts as a pharmacokinetic enhancer by inhibiting CYP3A-mediated metabolism, thereby increasing plasma concentrations of nirmatrelvir. This combination (marketed as Paxlovid) is approved for emergency use and treatment of COVID-19 in many countries.</p><h4>Pharmacokinetics</h4><p>Representative pharmacokinetic parameters for nirmatrelvir/ritonavir in healthy adult subjects after oral administration.</p><h4>References</h4><ol><li><p>Saravolatz, LD, et al., &amp; Sharma, M (2023). Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> 76(1) 165–171. DOI:<a href=&quot;https://doi.org/10.1093/cid/ciac180&quot;>10.1093/cid/ciac180</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35245942/&quot;>https://pubmed.ncbi.nlm.nih.gov/35245942</a></p></li><li><p>Hammond, J, et al., &amp; Rusnak, JM (2022). Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. <i>The New England journal of medicine</i> 386(15) 1397–1408. DOI:<a href=&quot;https://doi.org/10.1056/NEJMoa2118542&quot;>10.1056/NEJMoa2118542</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35172054/&quot;>https://pubmed.ncbi.nlm.nih.gov/35172054</a></p></li><li><p>Cox, DS, et al., &amp; Damle, B (2023). Effects of itraconazole and carbamazepine on the pharmacokinetics of nirmatrelvir/ritonavir in healthy adults. <i>British journal of clinical pharmacology</i> 89(9) 2867–2876. DOI:<a href=&quot;https://doi.org/10.1111/bcp.15788&quot;>10.1111/bcp.15788</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37184075/&quot;>https://pubmed.ncbi.nlm.nih.gov/37184075</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AE30;
